This week in Hematology
Nov 18, 2026
Carfilzomib-based strategies in transplant-eligible multiple myeloma: long-term follow-up of the phase 2 FORTE trial.
After about eight years, carfilzomib-lenalidomide-dexamethasone with autologous transplant gave a median progression-free survival of 98 months, and carfilzomib-lenalidomide maintenance prolonged progression-free survival without improving overall survival.
Blood · 2026 · PubMed
This week’s highlights
Read the weekly briefing
This AudioScholar briefing is generated by artificial intelligence from PubMed abstracts for healthcare professionals and is not medical advice.
This week: carfilzomib-based induction, transplant and maintenance hold their ground after eight years in myeloma, melphalan-based conditioning edges ahead for older transplant recipients, and a dual-target CAR T cell clears its first safety test.
Welcome to This Week in Hematology. We're covering 10 papers this week: 3 in depth, 4 in brief, 3 quick signals.
Bertuglia and colleagues report in Blood the long-term follow-up of FORTE [1], a randomised phase 2 trial in transplant-eligible patients aged 65 or younger with newly diagnosed multiple myeloma. Patients were first randomised to carfilzomib, lenalidomide and dexamethasone followed by autologous transplant, to twelve cycles of the same triplet without transplant, or to carfilzomib, cyclophosphamide and dexamethasone with transplant. They were then randomised again to carfilzomib plus lenalidomide maintenance or lenalidomide alone. With median follow-up of about eight years, the lenalidomide triplet with transplant reached a median progression-free survival of 98 months, against 70 months without transplant and 67 months with the cyclophosphamide triplet. Survival after the next line of therapy was also longer, and eight-year overall survival was 76 percent against 68 percent compared with the cyclophosphamide arm. Doublet maintenance cut the risk of progression by about a third versus lenalidomide alone, raised conversion to measurable residual disease negativity and reduced its resurgence, but it did not improve survival after the next line or overall survival. Second primary cancers occurred in 6 percent of patients. The main limitation is the phase 2 design, and the overall survival gain was shown only against the cyclophosphamide arm. The trial adds durable randomised evidence that transplant keeps its value after a carfilzomib triplet.
Also in Blood, Kongtim and colleagues used Center for International Blood and Marrow Transplant Research registry data from 2013 to 2022 to compare five fludarabine-based reduced-intensity regimens in 11,731 patients aged 50 or older with acute myeloid leukaemia or myelodysplastic syndromes undergoing allogeneic transplant [2]. Fludarabine was paired with two days of busulfan, with melphalan at 100 or 140 milligrams per square metre, or with 2 gray total body irradiation, with or without cyclophosphamide. After propensity weighting and a machine learning method called Bayesian additive regression trees, the fludarabine-melphalan regimens carried higher non-relapse mortality in the first six months. Beyond six months, both melphalan doses lowered the risk of death by about a fifth and outperformed every other regimen. Relapse was consistently lower with melphalan, late graft-versus-host-free, relapse-free survival improved, and in the most recent cohort the lower melphalan dose gave better disease-free survival than the irradiation regimens. The advantage held across comorbidity levels. The key limitation is the observational design: weighting cannot remove centre preference or unmeasured selection in who received which regimen. The study adds a very large comparative dataset, and the authors conclude that melphalan-based conditioning is the preferred platform, a conclusion still without randomised confirmation.
Staying with transplant, Wirbel and colleagues in Nature Medicine report BMT CTN 1801 [3], the microbiome companion to the randomised phase 3 trial 1703, which had shown post-transplant cyclophosphamide with mycophenolate to be superior to tacrolimus and methotrexate for graft-versus-host disease prophylaxis. Across 2575 stool samples from 304 co-enrolled participants, microbiome diversity at neutrophil engraftment was not associated with non-relapse mortality at one year, so the primary endpoint was not met. Lower diversity before transplant was associated with shorter overall survival. In exploratory analyses, diversity and total microbial load were lower with post-transplant cyclophosphamide between days 14 and 28, independent of other antibiotic exposure, and Clostridium scindens and secondary bile-acid pathways were less common in that arm. Single-species domination events did not differ between arms. The main limitation is that the negative primary result sits beside exploratory, hypothesis-generating findings. The study adds prospective evidence, collected inside a randomised trial, that does not confirm the engraftment-diversity link drawn from retrospective cohorts, and it shows that the prophylaxis regimen itself shapes the gut community, which complicates any test of microbiome-targeted interventions.
Now, four in brief.
Locatelli and colleagues in the American Journal of Hematology report a global, open-label, single-arm phase 3 trial of the C5 inhibitor ravulizumab in 41 children with transplant-associated thrombotic microangiopathy persisting despite initial management [4]. Complete response, the primary endpoint, occurred in 7 children, about one in six, and 22 more children had a partial response. Estimated overall survival was about 93 percent at day 100 and about 73 percent at one year. No meningococcal infections were reported, and three children had serious events judged related to the drug. Without a control arm and with a low complete response rate, the survival figures cannot be attributed to the drug with confidence.
Turning to myeloma, Hansen and colleagues in Blood Advances used Flatiron Health records to follow 683 patients with quadruple-class exposed disease, meaning prior proteasome inhibitor, immunomodulatory drug, anti-CD38 antibody and anti-BCMA therapy [5]. Of these, 241 patients started a further line and 121 patients died before any further therapy. In those treated, median event-free survival was 5 months and median overall survival about fifteen and a half months, and roughly a quarter of patients died before reaching each next line. GPRC5D bispecifics were the most common next regimen. This retrospective record-based study defines the baseline that the next two agents are measured against.
Baljevic and colleagues in Blood pooled phase 1 data on etentamig, an investigational BCMA by CD3 bispecific with a low-affinity CD3 arm, in 146 triple-class exposed patients with a median of four prior lines [6]. Objective responses occurred in about two thirds of patients, and very good partial response or better in just over half of patients, with median response duration and progression-free survival not reached at 13 months of median follow-up. Grade 3 or 4 neutropenia affected 38 percent of patients and serious infections 23 percent. In a 23-patient cohort with one step-up dose, cytokine release syndrome occurred in 30 percent, all grade 1 or 2. These are uncontrolled early data.
The Lancet carries the first-in-human phase 1 trial of TriPRIL [7], led by Puliafito, a CAR T cell built on a trimeric form of the natural ligand APRIL to target both BCMA and TACI, aimed at antigen escape. Fifteen patients at one Boston centre were infused, and nine of them had received prior BCMA-directed CAR T therapy. There were no dose-limiting toxicities. Cytokine release syndrome occurred in 13 of 15 patients, all grade 1 or 2, with one case each of grade 2 neurotoxicity and a grade 2 haemophagocytic-like syndrome, and no treatment-related deaths. The recommended phase 2 dose is 300 million cells. This is a small, single-centre safety study.
Three quick signals.
In Blood Cancer Journal, Matarasso Greenfeld and colleagues pooled 24 treatment arms with 2245 patients with relapsed follicular lymphoma [8]. Lenalidomide with rituximab produced responses in about three quarters of patients and complete responses in about 40 percent, lower in rituximab-refractory disease. Triplets raised complete responses but added grade 3 or higher toxicity. Heterogeneity across largely uncontrolled studies limits precision.
In the British Journal of Haematology, Stewart and colleagues studied 60 patients with chronic lymphocytic leukaemia after fixed-duration venetoclax with obinutuzumab or rituximab [9]. Among 29 patients with residual disease at end of treatment, 10 patients had lost CD20 expression, with NOTCH1 variants enriched, and the loss persisted for up to three years. This is a small retrospective series.
Also in the British Journal of Haematology, and also on chronic lymphocytic leukaemia resistance, Mashima and colleagues sequenced 122 of 646 patients treated with BTK inhibitors at Dana-Farber [10]. Progressing patients carried more BTK and PLCG2 mutations, more TP53, SF3B1, PPM1D and NOTCH2 mutations, and more complex karyotype with 8p loss. Single-centre, selective sequencing makes this hypothesis-generating.
Stepping back across this week's papers, the randomised evidence is thinner than the volume suggests. The one mature randomised trial shows gains in progression and residual disease that only partly carry through to survival, a prospective test of an association built on retrospective cohorts did not hold up, and the newest myeloma and transplant-complication therapies still rest on single-arm or single-centre data without comparators.
If you only have time for one paper this week, make it the long-term FORTE follow-up [1]. With mature randomised data, it settles whether autologous transplant still adds durable benefit after carfilzomib-based induction in younger patients with newly diagnosed myeloma.
That's your roundup for This Week in Hematology. The full transcript and references are available on the episode page. See you next week.
If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And think of one colleague, in any specialty, who never has time to keep up with the literature. Tell them about AudioScholar: a ten-minute weekly for every specialty, to listen to in any podcast app, or to read at audioscholar dot C C.
This is an automated summary generated by artificial intelligence, which can make mistakes. Use it to choose which papers to read in full.
Get Hematology every week
By email, Spotify, Apple or any podcast app.
Spot something worth flagging?